EMBC
Embecta Corp. NASDAQ Listed Mar 22, 2022$3.11
+0.65%
vs $3.09
Mkt Cap $184.5M
52w Low $2.77
2.7% of range
52w High $15.55
50d MA $5.43
200d MA $10.44
P/E (TTM)
1.9x
EV/EBITDA
4.6x
P/B
—
Debt/Equity
-2.2x
ROE
-22.8%
P/FCF
1.0x
RSI (14)
36.40
ATR (14)
$0.17
Beta
1.10
50d MA
$5.43
200d MA
$10.44
Avg Volume
2.9M
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
300 Kimball Drive · Parsippany, NJ 07054 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | BMO | 0.67 | 0.71 | +6.0% | 10.47 | +0.5% | +3.8% | +0.0% | -5.2% | -0.1% | -2.2% | — |
| Nov 25, 2025 | BMO | 0.70 | 0.50 | -28.6% | 13.58 | -1.6% | -7.4% | +0.0% | +1.5% | -4.0% | +0.4% | — |
| Aug 8, 2025 | BMO | 0.46 | 1.12 | +146.2% | 12.28 | +1.0% | +3.7% | +0.0% | +4.6% | +4.7% | -0.5% | — |
| May 9, 2025 | BMO | 0.66 | 0.70 | +6.1% | 11.97 | +4.1% | +3.7% | +0.0% | +0.7% | -7.3% | +0.6% | — |
| Feb 6, 2025 | BMO | 0.45 | 0.65 | +44.4% | 17.73 | -0.1% | -1.7% | +0.0% | +0.5% | +0.0% | -5.0% | — |
| Nov 26, 2024 | BMO | 0.36 | 0.45 | +25.0% | 18.70 | +4.7% | +10.1% | +0.0% | +1.2% | -1.0% | -0.9% | — |
| Aug 9, 2024 | BMO | 0.48 | 0.74 | +54.2% | 15.39 | -0.3% | -4.2% | +0.0% | +0.5% | -0.5% | -1.2% | — |
| May 9, 2024 | BMO | 0.43 | 0.67 | +55.8% | 14.16 | +2.8% | +0.6% | +0.0% | -0.4% | +3.0% | -5.8% | — |
| Feb 9, 2024 | BMO | 0.45 | 0.61 | +35.6% | 16.26 | -0.1% | -7.9% | +0.0% | -4.8% | +2.0% | +1.7% | — |
| Nov 21, 2023 | BMO | 0.42 | 0.59 | +40.5% | 17.06 | +2.4% | +3.3% | +0.0% | -0.7% | -0.6% | +0.7% | — |
| Aug 8, 2023 | BMO | 0.46 | 0.69 | +50.0% | 22.17 | -0.5% | -3.0% | +0.0% | -3.2% | +0.0% | -1.1% | — |
| May 12, 2023 | BMO | 0.50 | 0.75 | +50.0% | 30.69 | +0.4% | -6.5% | +0.0% | +0.5% | -3.1% | +1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6 | BTIG Research | Downgrade | Buy → Neutral | — | $3.90 | $3.99 | +2.3% | -8.7% | +1.1% | +1.1% | -7.7% | +1.5% |
| Apr 13 | Mizuho | Maintains | Neutral → Neutral | — | $8.85 | $8.81 | -0.5% | +4.6% | +2.2% | +1.6% | -1.0% | +2.8% |
| Feb 6 | BTIG | Maintains | Buy → Buy | — | $10.47 | $10.52 | +0.5% | +3.8% | -5.2% | -0.1% | -2.2% | -0.6% |
| Sep 5 | BTIG | Maintains | Buy → Buy | — | $14.49 | $14.48 | -0.1% | +3.2% | -2.1% | +4.0% | -1.7% | +2.3% |
| Jul 16 | Mizuho | Maintains | Neutral → Neutral | — | $9.58 | $9.68 | +1.0% | +1.8% | +1.0% | -0.7% | +5.2% | +3.9% |
| May 23 | Mizuho | Maintains | Neutral → Neutral | — | $10.51 | $10.40 | -1.0% | +2.0% | +5.0% | -6.3% | -0.9% | +0.7% |
| Nov 27 | BTIG | Upgrade | Neutral → Buy | — | $18.70 | $19.57 | +4.7% | +10.1% | +1.2% | -1.0% | -0.9% | +0.3% |
| Jul 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $13.17 | $12.90 | -2.1% | -2.5% | +2.8% | +3.0% | -1.8% | -1.3% |
| May 10 | Morgan Stanley | Maintains | Underweight → Underweight | — | $14.16 | $14.56 | +2.8% | +0.6% | -0.4% | +3.0% | -5.8% | +3.3% |
| Nov 22 | Morgan Stanley | Maintains | Underweight → Underweight | — | $17.06 | $17.47 | +2.4% | +3.3% | -0.7% | -0.6% | +0.7% | +3.4% |
| Oct 18 | Morgan Stanley | Maintains | Underweight → Underweight | — | $15.59 | $15.08 | -3.3% | -1.2% | -0.6% | +1.2% | +0.1% | +5.8% |
| Aug 24 | Morgan Stanley | Maintains | Underweight → Underweight | — | $17.65 | $17.28 | -2.1% | -4.0% | +1.2% | +1.8% | +3.8% | +1.3% |
| Jul 18 | Morgan Stanley | Maintains | Underweight → Underweight | — | $20.22 | $20.10 | -0.6% | -0.8% | -1.5% | +0.1% | +3.4% | -0.9% |
| May 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $30.69 | $30.80 | +0.4% | -6.5% | +0.5% | -3.1% | +1.8% | -5.0% |
| Jan 6 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $25.14 | $24.13 | -4.0% | -0.4% | -2.2% | +0.1% | -2.3% | -3.4% |
| Dec 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $27.40 | $27.40 | +0.0% | +2.4% | -0.5% | -1.4% | -2.5% | -3.7% |
| Oct 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $28.38 | $28.41 | +0.1% | -1.3% | +0.3% | +3.3% | -0.9% | +1.9% |
| Sep 8 | BTIG | Maintains | Neutral → Neutral | — | $32.02 | $31.35 | -2.1% | +1.3% | -0.1% | +2.1% | -3.6% | +1.9% |
| Aug 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $33.42 | $33.20 | -0.7% | -3.3% | +1.1% | +2.2% | +0.1% | -1.6% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.43 | $28.69 | -2.5% | +0.3% | +2.5% | -1.3% | -0.9% | +4.4% |
| Jun 21 | BofA Securities | Maintains | Underperform → Underperform | — | $28.26 | $27.01 | -4.4% | -4.5% | +5.1% | -4.8% | -0.6% | +0.5% |
No insider trades available.
8-K · 2.01
!!! Very High
Embecta Corp. -- 8-K 2.01: Acquisition Completed
May 15
8-K · 2.02
!! High
Embecta Corp. -- 8-K 2.02: Earnings Results
Embecta Corp. reported Q1 2026 earnings results, providing investors with updated financial performance and operational metrics for the quarter ended March 31, 2026.
May 5
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
This standard SEC boilerplate about furnishing documents upon request carries no material implications for EMBC's stock, as it merely describes routine regulatory compliance procedures rather than substantive business developments.
Mar 20
8-K
Embecta Corp. -- 8-K Filing
Embecta Corp. shareholders approved executive compensation packages for named officers through say-on-pay voting, indicating investor support for management's remuneration structure.
Feb 13
8-K
Embecta Corp. -- 8-K Filing
Embecta is prioritizing strengthening its injection product market leadership while expanding its portfolio and reducing debt to improve financial flexibility.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Yacktman Asset Management Lp | 3,671,877 | $32M | Added | Mar 2026 |
| 2 | River Road Asset Management, Llc | 3,449,502 | $30M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,563,951 | $23M | New | Mar 2026 |
| 4 | Deerfield Management Company, L.p. | 2,534,961 | $22M | Reduced | Mar 2026 |
| 5 | Morgan Stanley | 1,883,128 | $22M | Added | Dec 2025 |
| 6 | Millennium Management | 1,594,145 | $14M | Added | Mar 2026 |
| 7 | Walleye Capital Llc | 1,586,584 | $14M | New | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 1,537,957 | $14M | New | Mar 2026 |
| 9 | Sg Americas Securities, Llc | 1,038,948 | $9M | Added | Mar 2026 |
| 10 | Bank Of New York Mellon Corp | 823,787 | $7M | Added | Mar 2026 |
| 11 | Northern Trust Corp | 621,924 | $5M | Added | Mar 2026 |
| 12 | D.e. Shaw & Co | 532,328 | $5M | Reduced | Mar 2026 |
| 13 | Invesco Ltd. | 454,415 | $4M | Added | Mar 2026 |
| 14 | Principal Financial Group Inc | 336,231 | $4M | Added | Dec 2025 |
| 15 | Ubs Group Ag | 430,050 | $4M | Reduced | Mar 2026 |
| 16 | Marshall Wace, Llp | 421,273 | $4M | Added | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 393,609 | $3M | Added | Mar 2026 |
| 18 | Citadel Advisors Llc | 391,819 | $3M | Added | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 374,416 | $3M | Added | Mar 2026 |
| 20 | Aqr Capital Management Llc | 331,603 | $3M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$184.5M
Enterprise Value
$1.35B
P/E (TTM)
1.92x
Forward P/E
1.10x
PEG Ratio
0.42x
P/B
—
P/S
0.17x
P/FCF
1.00x
EV/EBITDA
4.57x
Shares Out
58.9M
Financials (TTM)
Revenue
$1.08B
Net Income
$95.4M
EBITDA
$294.7M
Free Cash Flow
$182.4M
Op Cash Flow
$191.7M
EPS Basic
$1.64
EPS Diluted
$1.62
EPS Forward
$2.81
Gross Margin
62.9%
Op Margin
30.5%
Net Margin
8.8%
Balance Sheet
Total Assets
$1.09B
Total Liab.
$1.74B
Total Equity
-$650.6M
Cash
$225.5M
LT Debt
$1.39B
Book Value/Sh
$-11.17
Debt/Equity
-2.20x
Current Ratio
2.41
Quick Ratio
1.73
Returns & Growth
ROE
-22.8%
ROA
13.1%
ROIC
27.4%
Rev Growth YoY
-3.8%
EPS Growth YoY
+20.6%
Price Returns
2W
+7.6%
1M
-63.1%
3M
-67.1%
6M
-73.5%
12M
-67.9%
Technicals
52W High
$15.55
52W Low
$2.77
50d MA
$5.43
200d MA
$10.44
RSI (14)
36.40
ATR (14)
$0.17
Beta
1.10
Avg Volume
2.9M
Dividends
Div Rate
$0.60
Div Yield
6.5%
Frequency
4
Ex-Div Date
Feb 27, 2026
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 25, 2026 7:03am
· Source: financialmodelingprep.com